Prolonged Exposure to Levetiracetam Reveals a Presynaptic Effect on Neurotransmission
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Summary: Purpose: The antiepileptic drug levetiracetam (LEV) is an enigma. Despite the fact that it specifically binds to the presynaptic vesicle protein, SV2A, no satisfactory mechanism of action has yet been identified. Using a combination of electrophysiological and cellular imaging techniques, we carefully tested the hypothesis that LEV directly interferes with neurotransmitter release. Methods: We measured extracellular evoked responses in the CA1 region of rat hippocampal slices after paired pulse stimulation and after application of up to 10 pulses applied at 5–80 Hz. In parallel experiments, we used quantitative 2‐photon microscopy and the fluorescent vesicular marker FM1–43 to measure the effect of repetitive stimulation on presynaptic vesicle release. Results: Acute exposure to LEV (100 μM) had no effect on paired pulse synaptic responses. However, when slices were exposed to LEV for 3 h, there was a significant alteration in paired pulse responses and a more striking reduction in late synaptic potentials delivered in an 80 Hz train. LEV significantly reduced the rate of vesicle release assessed by FM1–43 destaining during 1 Hz stimulation. Conclusion: LEV is unique among currently available antiepileptics, because it directly inhibits presynaptic neurotransmitter release in a use‐dependent fashion. While there are alternate explanations for this observation, it is plausible that LEV exerts its effect by binding to a protein selectively expressed in presynaptic nerve terminals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Südhof, T. C. (2004) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.041002.131412 · Cited by 2,547 · cited 3×
“…exerts some presynaptic effect, but do not resolve whether there is interference with vesicle docking, delayed mobilization of a readily releasable pool of vesicles, or retention of FM1–43 (and transmitter) within the vesicular matrix (Gandhi and Stevens, 2003; Reigada et al., 2003; Sudhof, 2004).”
BackgroundThe synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 2×
“The most attractive clue to a mechanism has come from experiments which show that LEV binds to a specific vesicular presynaptic membrane protein, SV2A, and that an enantiomer, ucb L060, lacking antiepileptic properties fails to bind to the same site (Lynch et al., 2004).”
BackgroundVisualization of changes in presynaptic function during long-term synaptic plasticity
Zakharenko, S. S., Zablow, L., & Siegelbaum, S. A. (2001) · Nature Neuroscience · doi:10.1038/89498 · Cited by 305
Synaptic vesicle protein 2 enhances release probability at quiescent synapses
Custer, K. L., Austin, N. S., Sullivan, J. M., & Bajjalieh, S. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2699-05.2006 · Cited by 211
Cited by
Network abnormalities and interneuron dysfunction in Alzheimer disease
Palop, J. J., & Mucke, L. (2016) · Nature reviews. Neuroscience · doi:10.1038/nrn.2016.141 · Cited by 1,022
Löscher, W., & Brandt, C. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003046 · Cited by 414
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H. (2016) · CNS Drugs · doi:10.1007/s40263-016-0384-x · Cited by 184
“in brain slices was found to be a reduction in exocytosis [89]; however, the underlying mechanistic effect of ligand binding is not fully elucidated.”
BackgroundInfluentialLevetiracetam Mechanisms of Action: From Molecules to Systems
Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040475 · Cited by 131
“In contrast, LEV decreased excitatory and inhibitory synaptic currents in an in vitro study of whole cell patch recordings, which suggest that LEV binds to SV2A and reduces presynaptic neurotransmitter release [122,216].”
BackgroundSynaptic Vesicle Glycoprotein 2A: Features and Functions
Rossi, R., Arjmand, S., Bærentzen, S. L., Gjedde, A., & Landau, A. M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.864514 · Cited by 123
“Electrophysiological and cellular imaging techniques revealed that prolonged exposure to levetiracetam reduces the rate of release of pre-synaptic vesicles, which is consistent with the localization and the hypothesized functions of the target SV2A (Yang et al., 2007).”
Background
Metadata
- Authors
- Yang, X., Weisenfeld, A., & Rothman, S. M.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2007-05-23
- Volume
- 48
- Issue
- 10
- Pages
- 1861-1869
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2080196512
- Cited by
- 111
- References
- 4
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prolonged Exposure to Levetiracetam Reveals a Presynaptic Effect on Neurotransmission. https://app.cochat.ai/papers/10.1111/j.1528-1167.2006.01132.x
- The paper
- Yang, X., Weisenfeld, A., & Rothman, S. M. (2007). Prolonged Exposure to Levetiracetam Reveals a Presynaptic Effect on Neurotransmission. Epilepsia. https://doi.org/10.1111/j.1528-1167.2006.01132.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.